Chinese Journal of Dermatology ›› 2018, Vol. 51 ›› Issue (5): 328-331.doi: 10.3760/cma.j.issn.0412-4030.2018.05.002
Previous Articles Next Articles
Xiaohong Su
Received:2018-03-14
Revised:2018-04-10
Online:2018-05-15
Published:2018-05-02
Contact:
Xiaohong Su
E-mail:suxh@ncstdlc.org
Xiaohong Su. Challenges to diagnosis and treatment of Mycoplasma genitalium infection[J].Chinese Journal of Dermatology, 2018, 51(5): 328-331.
| ［1］ | Baumann L, Cina M, Egli⁃Gany D, et al. Prevalence of Mycoplasma genitalium in different population groups: systematic review and meta⁃analysis［J］. Sex Transm Infect, 2018. ［published online ahead of print Feb 9, 2018］. doi: 10.1136/sextrans⁃2017⁃053384.<br /> |
| ［2］ | Jensen JS, Cusini M, Gomberg M, et al. 2016 European guideline on Mycoplasma genitalium infections［J］. J Eur Acad Dermatol Venereol, 2016,30（10）:1650⁃1656. doi: 10.1111/ jdv. 13849.<br /> |
| ［3］ | Getman D, Jiang A, O′Donnell M, et al. Mycoplasma genitalium prevalence, coinfection, and macrolide antibiotic resistance frequency in a multicenter clinical study cohort in the United States［J］. J Clin Microbiol, 2016,54（9）:2278⁃2283. doi: 10.1128/JCM.01053⁃16.<br /> |
| ［4］ | Gratrix J, Plitt S, Turnbull L, et al. Prevalence and antibiotic resistance of Mycoplasma genitalium among STI clinic attendees in Western Canada: a cross⁃sectional analysis［J］. BMJ Open, 2017,7（7）:e016300. doi: 10.1136/bmjopen⁃2017⁃016300.<br /> |
| ［5］ | Lockhart A, Psioda M, Ting J, et al. Prospective evaluation of cervico⁃vaginal self and cervical physician⁃collection for the detection of Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium infections［J］. Sex Transm Dis, 2018. https://insights.ovid.com/pubmed?pmid=29465667. ［published online ahead of print Jan 2, 2018］. doi: 10.1097/OLQ.0000000000000778.<br /> |
| ［6］ | Zheng BJ, Yin YP, Han Y, et al. The prevalence of urethral and rectal Mycoplasma genitalium among men who have sex with men in China, a cross⁃sectional study［J］. BMC Public Health, 2014,14:195. doi: 10.1186/1471⁃2458⁃14⁃195.<br /> |
| ［7］ | Chen LS, Wu JR, Wang B, et al. Epidemiology of Mycoplasma acquisition in male HIV⁃1 infected patients: a multistage cross⁃sectional survey in Jiangsu, China［J］. Epidemiol Infect, 2015,143（15）:3327⁃3334. doi: 10.1017/S0950268815000461.<br /> |
| ［8］ | Zheng BJ, Yin YP, Xiang Z, et al. An epidemiological study of Mycoplasma genitalium infections among males attending a sexually transmitted disease clinic in Guangxi, China［J］. Jpn J Infect Dis, 2014,67（1）:17⁃21.<br /> |
| ［9］ | Moi H, Reinton N, Moghaddam A. Mycoplasma genitalium is associated with symptomatic and asymptomatic non⁃gonococcal urethritis in men［J］. Sex Transm Infect, 2009,85（1）:15⁃18. doi: 10.1136/sti.2008.032730.<br /> |
| ［10］ | Gaydos CA. Mycoplasma genitalium: accurate diagnosis is necessary for adequate treatment［J］. J Infect Dis, 2017,216（suppl 2）:S406⁃406S411. doi: 10.1093/infdis/jix104.<br /> |
| ［11］ | Smieszek T, White PJ. Apparently⁃Different Clearance Rates from cohort studies of Mycoplasma genitalium are consistent after accounting for incidence of infection, recurrent infection, and study design［J］. PLoS One, 2016,11（2）:e0149087. doi: 10.1371/journal.pone.0149087.<br /> |
| ［12］ | Bradshaw CS, Jensen JS, Waites KB. New horizons in Mycoplasma genitalium treatment［J］. J Infect Dis, 2017,216（suppl 2）:S412⁃412S419. doi: 10.1093/infdis/jix132.<br /> |
| ［13］ | Bradshaw CS, Jensen JS, Tabrizi SN, et al. Azithromycin failure in Mycoplasma genitalium urethritis［J］. Emerg Infect Dis, 2006,12（7）:1149⁃1152. doi: 10.3201/eid1207.051558.<br /> |
| ［14］ | Lau A, Bradshaw CS, Lewis D, et al . The efficacy of azithromycin for the treatment of genital Mycoplasma genitalium: a systematic review and meta⁃ analysis ［J］. Clin Infect Dis, 2015,61（9）:1389⁃1399. doi: 10.1093/cid/civ644.<br /> |
| ［15］ | Gesink D, Racey CS, Seah C, et al. Mycoplasma genitalium in Toronto, Ont: estimates of prevalence and macrolide resistance［J］. Can Fam Physician, 2016,62（2）:e96⁃101.<br /> |
| ［16］ | Pitt R, Fifer H, Woodford N, et al. Detection of markers predictive of macrolide and fluoroquinolone resistance in Mycoplasma genitalium from patients attending sexual health services in England［J］. Sex Transm Infect, 2018,94（1）:9⁃13. doi: 10.1136/sextrans⁃2017⁃053164.<br /> |
| ［17］ | Tabrizi SN, Su J, Bradshaw CS, et al. Prospective evaluation of resistance plus MG, a new multiplex quantitative PCR assay for detection of Mycoplasma genitalium and macrolide resistance［J］. J Clin Microbiol, 2017,55（6）:1915⁃1919. doi: 10.1128/JCM. 02312⁃16.<br /> |
| ［18］ | Basu I, Roberts SA, Bower JE, et al. High macrolide resistance in Mycoplasma genitalium strains causing infection in Auckland, New Zealand［J］. J Clin Microbiol, 2017,55（7）:2280⁃2282. doi: 10.1128/JCM.00370⁃17.<br /> |
| ［19］ | Li Y, Le WJ, Li S, et al. Meta⁃analysis of the efficacy of moxi⁃floxacin in treating Mycoplasma genitalium infection［J］. Int J STD AIDS, 2017,28（11）:1106⁃1114. doi: 10.1177/0956462416688562.<br /> |
| ［20］ | Soni S, Parkhouse A, Dean G. Macrolide and quinolone⁃resistant Mycoplasma genitalium in a man with persistent urethritis: the tip of the British iceberg?［J］. Sex Transm Infect, 2017,93（8）:556⁃557. doi: 10.1136/sextrans⁃2016⁃053077.<br /> |
| ［21］ | Couldwell DL, Tagg KA, Jeoffreys NJ, et al. Failure of moxi⁃floxacin treatment in Mycoplasma genitalium infections due to macrolide and fluoroquinolone resistance［J］. Int J STD AIDS, 2013,24（10）:822⁃828. doi: 10.1177/0956462413502008.<br /> |
| ［22］ | Anderson T, Coughlan E, Werno A. Mycoplasma genitalium macrolide and fluoroquinolone resistance detection and clinical implications in a selected cohort in New Zealand［J］. J Clin Microbiol, 2017,55（11）:3242⁃3248. doi: 10.1128/JCM.01087⁃17.<br /> |
| ［23］ | Barberá MJ, Fernández⁃Huerta M, Jensen JS, et al. Mycoplasma genitalium macrolide and fluoroquinolone resistance: prevalence and risk factors among a 2013⁃2014 cohort of patients in Barcelona, Spain［J］. Sex Transm Dis, 2017,44（8）:457⁃462. doi: 10.1097/OLQ.0000000000000631.<br /> |
| ［24］ | Deguchi T, Yasuda M, Horie K, et al. Drug resistance⁃associated mutations in Mycoplasma genitalium in female sex workers, Japan［J］. Emerg Infect Dis, 2015,21（6）:1062⁃1064. doi: 10.3201/eid2106.142013.<br /> |
| ［25］ | Murray GL, Bradshaw CS, Bissessor M, et al. Increasing macrolide and fluoroquinolone resistance in Mycoplasma genitalium［J］. Emerg Infect Dis, 2017,23（5）:809⁃812. doi: 10.3201/eid2305. 161745.<br /> |
| ［26］ | Shimada Y, Deguchi T, Nakane K, et al. Emergence of clinical strains of Mycoplasma genitalium harbouring alterations in ParC associated with fluoroquinolone resistance［J］. Int J Antimicrob Agents, 2010,36（3）:255⁃258. doi: 10.1016/j.ijantimicag.2010. 05.011.<br /> |
| ［27］ | TRH R, Jensen JS, Fairley CK, et al. Use of pristinamycin for macrolide⁃resistant Mycoplasma genitalium infection［J］. Emerg Infect Dis, 2018,24（2）:328⁃335. doi: 10.3201/eid2402.170902.<br /> |
| ［28］ | Falk L, Jensen JS. Successful outcome of macrolide⁃resistant Mycoplasma genitalium urethritis after spectinomycin treatment: a case report［J］. J Antimicrob Chemother, 2017,72（2）:624⁃625. doi: 10.1093/jac/dkw405.<br /> |
| ［29］ | Deguchi T, Ito S, Yasuda M, et al. Emergence of Mycoplasma genitalium with clinically significant fluoroquinolone resistance conferred by amino acid changes both in GyrA and ParC in Japan［J］. J Infect Chemother, 2017,23（9）:648⁃650. doi: 10.1016/j.jiac.2017.03.008.<br /> |
| No related articles found! |
|
